Ramipril Capsule
Product Images NDC 51655-347

4 FDA label images from Northwind Health Company, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655 347 52 Master Bottle Label Approval Rev A 10 20

51655 347 52 Master Bottle Label Approval   Rev A 10 20
Label for Ramipril Capsules USP 2.5 mg by Northwind Health Company, LLC, packaged in a bottle containing 30 capsules. The label includes NDC 51655-347-52, directions to see package insert for dosage, and storage instructions at 20°-25°C (68°-77°F). It also notes the product is prescription only.*
FDA Label Image

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 01

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 01
Chemical structure diagram of Ramipril showing the molecular arrangement of atoms and bonds specific to this active ingredient in the drug Ramipril.*
FDA Label Image

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 02

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 02
A line graph showing the proportion of patients over days of follow-up for Ramipril versus placebo groups. The x-axis represents days of follow-up up to about 1600 days, and the y-axis shows the proportion of patients up to 0.20. Two lines are plotted: a solid line for Ramipril and a dashed line for placebo, with a noted p-value of 0.0001 indicating statistical comparison.*
FDA Label Image

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 03

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 03
A forest plot chart showing the relative risk of a composite outcome in the Ramipril group versus placebo. It compares incidence rates across various patient subgroups, including cardiovascular disease, diabetes, age, sex, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The x-axis displays relative risk values with 95% confidence intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.